Tyra Biosciences announces $200M private placement led by RA Capital at $13.01/share

Tyra Biosciences, Inc.

Gross proceeds of approximately $200 million from sale of ~15.4 million shares/pre-funded warrants at $13.01 per share.
Financing led by RA Capital Management with participation from Boxer Capital, BVF Partners, Nextech, OrbiMed, 5AM Ventures.
Proceeds to advance clinical development of TYRA-300 and TYRA-200, preclinical programs, and for working capital.
PIPE expected to close on February 6, 2024, subject to customary closing conditions.
Company to file resale registration statement with SEC within 45 days after closing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tyra Biosciences, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $200 million (effective 2024-02-01).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers named therein
Value: approximately $200 million
Effective: 2024-02-01

Exact text from the filing

On February 1, 2024, Tyra Biosciences, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agreement) with the purchasers named therein (the Purchasers), for the private placement (the Private Placement) of (i) 9,286,023 shares (the Shares) of the Company’s common stock

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-023367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.